Marc Ferrante

Dr Marc Ferrante is associated professor of Gastroenterology and Hepatology at KU Leuven (Leuven, Belgium) since 2013. Marc Ferrante started his own research group in close collaboration with the Stem Cell Institute of Leuven and the inflammatory bowel disease (IBD) team. His group is currently focusing on the influence of microbiota on intestinal stem cell behaviour and differentiation in patients with IBD. Besides his translational work, Marc Ferrante is highly involved in the clinical IBD trial centre of the University Hospitals Leuven.
Marc Ferrante has published more than 200 papers (h-index: 43) and received numerous research awards. He was awarded as a Rising Star in Gastroenterology at the European Congress of Gastroenterology in 2014. Marc Ferrante holds a basic clinical research position at the Flemish Foundation for Scientific Research (FWO Vlaanderen). He is board member and treasurer of the Belgian IBD Research and Development group, member of the Scientific Committee of the European Crohn’s and Colitis Organization (ECCO), and previous chair of both the ECCO Clinical Committee and Young ECCO.

Rates of Post-operative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies

Quality of care in an inflammatory bowel disease clinical trial center : a prospective study evaluating patients' satisfaction

Short-and long-term outcomes following side-to-side strictureplasty and its modification over the ileocecal valve for extensive Crohn's ileitis

Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease

Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy

Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations

Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding

Belgian IBD Research Group (BIRD) Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases

Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease Patients

Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study

Inflammatory Bowel Disease (IBD)-A Textbook Case for Multi-Centric Banking of Human Biological Materials

Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.

Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease

Ulcerative colitis treatment : an insight into daily clinical practice

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Disease

Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center

A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis

New biologics and small molecules in inflammatory bowel disease: an update

Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease

Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease

Editorial: biomarker predictors of non-response to TNFα antagonists - the quest continues. Authors' reply

Butyrate Does Not Protect Against Inflammation-induced Loss of Epithelial Barrier Function and Cytokine Production in Primary Cell Monolayers From Patients With Ulcerative Colitis

Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decade

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease

Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease

Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease

Optimising infliximab induction dosing for patients with ulcerative colitis

Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease

Effects of Epithelial IL-13Rα2 Expression in Inflammatory Bowel Disease.

Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients

Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information.

Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

When IBD is not IBD.

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Failure of MMP-9 Antagonists in IBD: Demonstrating the Importance of Molecular Biology and Well-Controlled Early Phase Studies

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study

Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD)

Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab

New treatment options for inflammatory bowel diseases

The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease

Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response

Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease

Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab

Outcome of restorative proctocolectomy with an ileo-anal pouch for ulcerative colitis: effect of changes in clinical practice

Biopsy-derived Intestinal Epithelial Cell Cultures for Pathway-based Stratification of Patients With Inflammatory Bowel Disease

Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model

Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial

Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC